Tarka and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is reported as a side effect among people who take Tarka (trandolapril; verapamil hydrochloride), especially for people who are female, 60+ old, also take Norvasc, and have Constipation.

The phase IV clinical study analyzes which people have Chronic obstructive pulmonary disease when taking Tarka. It is created by eHealthMe based on reports of 2,361 people who have side effects when taking Tarka from the FDA, and is updated regularly.

What is Tarka?

Tarka has active ingredients of trandolapril; verapamil hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 2,409 Tarka users. Check the latest studies of Tarka.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,807 drugs and 2,206 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.

On Jul, 13, 2026

2,361 people reported to have side effects when taking Tarka.
Among them, 14 people (0.59%) have Chronic obstructive pulmonary disease.

Could Tarka cause Chronic obstructive pulmonary disease?

Among these 14 people:

What is the gender of people who have Chronic obstructive pulmonary disease when taking Tarka? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Chronic obstructive pulmonary disease when taking Tarka? *

What are other drugs people take besides Tarka? *

What are other side effects people have besides Chronic obstructive pulmonary disease? *

Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 5 people, 35.71%
Pneumonia: 4 people, 28.57%
Sinusitis (inflammation of sinus): 4 people, 28.57%
Stress And Anxiety: 4 people, 28.57%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 4 people, 28.57%
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body): 4 people, 28.57%
Hypokalemia (low potassium): 4 people, 28.57%
Upper Respiratory Tract Infection: 4 people, 28.57%
Head Injury: 4 people, 28.57%
Inflammation: 3 people, 21.43%

What are the existing conditions these people have? *

Stress And Anxiety: 1 person, 7.14%
Secretion Discharge: 1 person, 7.14%
Pain: 1 person, 7.14%
Osteoporosis (bones weak and more likely to break): 1 person, 7.14%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 7.14%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 7.14%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 7.14%
Dyspnea (difficult or laboured breathing): 1 person, 7.14%
Cough: 1 person, 7.14%
Constipation: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Tarka and have Chronic obstructive pulmonary disease?

- Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarka:

Tarka (2,409 reports)

Chronic obstructive pulmonary disease treatments and more:

Chronic obstructive pulmonary disease (198,253 reports)

How severe was Chronic obstructive pulmonary disease and when was it recovered:

Chronic obstructive pulmonary disease in Tarka

Expand to all the drugs that have ingredients of trandolapril; verapamil hydrochloride:

Chronic obstructive pulmonary disease and drugs with ingredients of trandolapril; verapamil hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tarka:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (1,807 drugs)

Browse all the conditions that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (2,206 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on trandolapril; verapamil hydrochloride (the active ingredients of Tarka) and Tarka (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.